Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer

JAMA

Volumn 282, Issue 14, 1999, Pages 1335-1343

  Rowlings, Philip A ^b   Williams, Stephanie F ^b   Antman, Karen H ^b   Fields, Karen K ^b   Fay, Joseph W ^b   Reed, Elizabeth ^b   Pelz, Corey J ^b   Klein, John P ^b   Sobocinski, Kathleen A ^b   Kennedy, M John ^b   Freytes, Cesar O ^b   McCarthy, Philip L ^b   Herzig, Roger H ^b   Stadtmauer, Edward A ^b   Lazarus, Hillard M ^b   Pecora, Andrew L ^b   Bitran, Jacob D ^b   Wolff, Steven N ^b   Gale, Robert Peter ^b   Armitage, James O ^b   Vaughan, William P ^b   Spitzer, Gary ^b   Horowitz, Mary M ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; THIOTEPA; VINBLASTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 0033552263     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.14.1335     Document Type: Article

References (35)

1. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia, Pa: JB Lippincott Co; 1993:1264-1332.
2. Antman KH, Bowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
3. Gradishar WJ, Tallman MS, Abrams JS. High-dose chemotherapy for breast cancer. Ann Intern Med. 1996;125:599-604.
4. United States General Accounting Office. Report to the Honorable Ron Wyden, U.S. Senate: Health Insurance: Coverage of Autologous Bone Marrow Transplantation for Breast Cancer. Gaithersburg, Md: US General Accounting Office; 1996. GAO/HEHS-96-83.
5. Peters WP, Rogers MC. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med. 1994;330:473-477.
6. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
7. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol. 1989;7:1824-1830.
8. Dunphy FR, Spitzer G, Buzdar AU, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol. 1990;8:1207-1216.
9. Wallerstein R Jr, Spitzer G, Dunphy F, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol. 1990;8:1782-1788.
10. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991;83:920-926.
11. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992;10:102-110.
12. Ayash LJ, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for meta-static breast cancer: a feasibility study. J Clin Oncol. 1994;12:37-44.
13. Dunphy FR, Spitzer G, Fomoff JE, et al. Factors predicting long-term survival for metastatic breast cancer patents treated with high-dose chemotherapy and bone marrow support [published correction appears in Cancer. 1994;74:773]. Cancer. 1994;73:2157-2167.
14. Dunphy FR, Spitzer G, Fomoff JE, et al. Factors predicting long-term survival for metastatic breast cancer patents treated with high-dose chemotherapy and bone marrow support [published correction appears in Cancer. 1994;74:773]. Cancer. 1994;73:2157-2167.
15. Vaughan WP, Reed EC, Edwards B, Kessinger A. High-dose cyclophosphamide, thiotepa and hydroxy-urea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant. 1994;13:619-624.
16. Ayash LJ, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995;13:2043-2049.
17. Weaver CH, West WH, Schwartzberg LS, et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant. 1997;19:661-670.
18. Bensinger WI, Schiffman KS, Holmberg L, et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant. 1997; 19:1183-1189.
19. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483-2489.
20. Kennedy MJ. High-dose chemotherapy of breast cancer: is the question answered [comment]? J Clin Oncol. 1995;13:2477-2479.
21. Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979;39: 1552-1562.
22. Nash CH III, Jones SE, Moon TE, Davis SL, Salmon SE. Prediction of outcome in metastatic breast cancer treated with Adriamycin combination chemotherapy. Cancer. 1980;46:2380-2388.
23. Ahmann FR, Jones SE, Moon TE. The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol. 1988;37:116-122.
24. Falkson G, Gelman RS, Leone L, Falkson CI. Survival of premenopausal women with metastatic breast cancer: long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer. 1990;66:1621-1629.
25. Falkson G, Gelman R, Falkson CI, Glick J, Harris J. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol. 1991; 9:2153-2161.
26. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197-2205.
27. Henderson IC, Harris JR, Kinne DW, Hellman S. Cancer of the breast. In: DeVita VT Jr. Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1989:1197-1268.
28. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics. National Hospital Discharge Survey for 1990 and 1991. Hyattsville, Md: Hospital Care Statistics Branch, National Center for Health Statistics. 1992.
29. Graves EJ. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1989. Vital Health Stat 13. 1991;108:1-236.
30. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer-Verlag; 1997.
31. Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal. 1995; 1:145-156.
32. Peters WP, Jones RB, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy [abstract]. Proc Am Soc Clin Oncol. 1996;15:121.
33. Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997;15:3171-3177.
34. Garcia-Carbonera R, Hidalgo M, Paz-Ares L, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol. 1997;15:3178-3184.
35. Stadtmauer EA, O'Neil P, Goldstein LJ, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracll (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the "Philadelphia" Intergroup Study (PBT-1) [abstract]. Proc Am Soc Clin Oncol. 1999;18:1a.